证券代码：688176 证券简称：亚虹医药 公告编号：2025-045 江苏亚虹医药科技股份有限公司 自愿披露关于在第 19 届欧洲结直肠大会（ECC）发 布 APL-1401 Ⅰb 期临床试验相关数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 肠癌的风险。目前尚无治愈 UC 的方法，现有疗法的有效性和安全性仍存在进一 步提升的空间，存在巨大未被满足的临床需求，亟需新机制的疗法。 重要内容提示： 1、近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）开展的 APL-1401 用于治疗中重度活动性溃疡性结肠炎的 Ⅰb 期临床试验（以下简称"该 研究"）结果入选第 19 届欧洲结直肠大会（European Colorectal Congress，ECC）， 并以壁报形式发布该研究的临床数据。 2、目前上述在研产品尚处于临床试验早期阶段，未来临床试验结果能否支 持药品递交上市申请、能否最终获得上市批准以及何时获批均具有不确定性，产 品获批后能否最终实现预期商业目的也存在一定的不确定性。本次发表临床试验 数据， ...

Core Viewpoint - The company announced that its clinical trial results for APL-1401, aimed at treating moderate to severe active ulcerative colitis, have been selected for presentation at the 19th European Colorectal Congress (ECC) in the form of a poster [1] Group 1 - The clinical trial for APL-1401 is in the Phase Ib stage [1] - The results of the trial have been recognized and will be shared at a significant industry event, indicating potential interest and validation from the medical community [1]

Core Viewpoint - Aihong Pharmaceutical (688176) announced the results of its APL-1401 clinical trial for moderate to severe active ulcerative colitis, which were presented at the 19th European Colorectal Congress [1] Group 1: Clinical Trial Information - APL-1401 is an innovative oral drug developed by the company, targeting autoimmune diseases with a novel mechanism of action [1] - The clinical trial is currently in the early stages, and there is uncertainty regarding whether the results will support a drug submission for market approval and when such approval might occur [1]

Group 1 - The core point of the article highlights that Yahui Pharmaceutical (688176.SH) is currently trading at 9.95 yuan, reflecting a decline of 2.26% and is in a state of share price decline since its IPO [1] - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share, underwritten by CITIC Securities [1] - The stock price fell below the IPO price on the first trading day, reaching a maximum price of 20.00 yuan, which was the highest price since its listing [1] Group 2 - The total funds raised from the initial public offering (IPO) amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs, exceeding the original plan by 311 million yuan [1] - The funds are intended for projects including drug and medical device production, new drug research and development, marketing network construction, and working capital supplementation [1] - The total issuance costs for the IPO were 147 million yuan, with CITIC Securities receiving 130 million yuan in underwriting and sponsorship fees [1] Group 3 - The controlling shareholder and actual controller of Yahui Pharmaceutical is PAN KE, who holds American nationality and serves as the chairman and general manager of the company [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-044 江苏亚虹医药科技股份有限公司 关于变更签字注册会计师的公告 二、本次变更人员的基本信息、诚信记录和独立性情况 1、基本信息 1 王子竹女士，于 2022 年成为注册会计师，2017 年开始从事上市公司审计， 2017 年开始在立信会计师事务所执业，2025 年开始为公司提供审计服务。王子 竹女士近三年从业情况如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 18 日召开第二届董事会第十四次会议、2025 年 5 月 23 日召开 2024 年年度股 东大会，审议通过了《关于续聘公司 2025 年度审计机构的议案》，同意续聘立 信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"）担任公司 2025 年度审计机构，具体内容详见公司分别于 2025 年 4 月 19 日、2025 年 5 月 24 日在上海证券交易所网站（www.sse.com.cn）披露的《江苏 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-043 一、说明会类型 本次投资者说明会以视频结合网络互动的方式召开，公司将针对 2025 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 1 会议召开时间：2025 年 11 月 27 日（星期四）13:00-14:45 会议召开地点：上海证券交易所上证路演中心 会议召开方式：上证路演中心视频结合网络互动 投资者可于 2025 年 11 月 20 日（星期四）至 11 月 26 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 securities@asieris.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 江苏亚虹医药科技股份有限公司 关于召开 2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 江苏亚 ...

Core Viewpoint - Yahui Pharmaceutical (688176) has seen a stock price increase of 4.31% this week, closing at 10.16 RMB as of November 14, 2025, with a total market capitalization of 5.803 billion RMB [1] Company Announcements - Yahui Pharmaceutical has completed a change in registered capital, with the new registered capital amounting to 571.170486 million RMB [1] - The company held a board and supervisory board meeting on August 28, 2025, and an extraordinary shareholders' meeting on September 23, 2025, where it approved the cancellation of the supervisory board, change in registered capital, and amendments to the company’s articles of association [1] - The company has received a new business license from the Taizhou Market Supervision Administration reflecting the changes in registered capital [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-042 江苏亚虹医药科技股份有限公司 关于完成注册资本变更并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日 召开第二届董事会第十八次会议、第二届监事会第十四次会议，于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会，审议通过了《关于取消监事会、变更注 册资本、修订<公司章程>并办理工商变更登记的议案》，同意公司取消监事会、 注册资本变更、修订《江苏亚虹医药科技股份有限公司章程》并办理工商变更登 记。具体内容详见公司分别于 2025 年 8 月 29 日、2025 年 9 月 24 日披露于上海 证券交易所网站（www.sse.com.cn）的《江苏亚虹医药科技股份有限公司关于取 消监事会、变更注册资本、修订<公司章程>并办理工商变更登记及修订、制定 公司部分治理制度的公告》（公告编号：2025-034）、《江苏亚虹医药科技股份有 限公司 ...

Core Insights - A new investment fund named Changzhou Liyang Qifan New Industry Investment Fund Partnership (Limited Partnership) has been established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes private equity investment, investment management, and asset management activities [1] - The fund is co-held by companies such as Yahu Pharmaceutical and Silergy Semiconductor Technology (Hangzhou) Co., Ltd [1]

Core Points - The stock price of Yahui Pharmaceutical (688176.SH) closed at 9.81 yuan, reflecting a decline of 1.6% and indicating a state of breaking issue [1] - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share [1] - The stock experienced a break on its first trading day, with an intraday high of 20.00 yuan, which remains the highest price since its listing [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 311 million yuan, with the company initially aiming to raise 2.070 billion yuan [1] - The total issuance costs for the IPO amounted to 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Project Allocation - The funds raised are intended for various projects, including drug and medical device production, new drug research and development, marketing network construction, and supplementing working capital [1] Company Leadership - The controlling shareholder, actual controller, chairman, and general manager of Yahui Pharmaceutical is PAN KE, who holds American nationality [1]